Galapagos NV operates in the Commercial physical research sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Galapagos NV with three other
miscellaneous service companies in Europe:
Bachem Holding AG
sales of 236.48 million Swiss Francs [US$243.04 million]
of which 89%
was Active Pharmaceutical Ingredients),
Bavarian Nordic AS
(1.01 billion Danish Kroner [US$158.86 million]
Pharma Mar SA
based in Spain
(180.95 million Euro [US$212.38 million]
of which 62%
was Biotech Sector).
Sales increased substantially in 2016:
Galapagos NV reported sales of 151.61 million Euro (US$177.95 million)
December of 2016.
increase of 150.3%
versus 2015, when the company's sales were 60.58 million Euro.
Sales of R&d saw an increase
121.5% in 2016, from
54.91 million Euro to 121.62 million Euro.
Not all segments of Galapagos NV experienced an increase in sales in 2016:
sales of Fee-For-Services fell 29.0% to 7.90 million Euro.